ABCL vs DYN: stock comparison and AI forecast
Abcellera Biologics Inc. (ABCL) and Dyne Therapeutics, Inc. (DYN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABCL Abcellera Biologics Inc.
- Price
- $11.12 +142.3% · 6M
- Market Cap
- $3.41B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
DYN Dyne Therapeutics, Inc.
- Price
- $17.30 -2.3% · 6M
- Market Cap
- $3.23B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ABCL and DYN have similar market capitalizations ($3.41B and $3.23B).
- Over the last six months ABCL returned +142.3% and DYN -2.3%.
- ABCL carries 0.46 times debt per unit of equity, against 0.42 times for DYN.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABCL | DYN |
|---|---|---|
| Market Cap | $3.41B | $3.23B |
| P/B Ratio | 3.81x | 4.60x |
| EPS | $-0.55 | $-2.53 |
| Book Value/Share | $2.92 | $3.76 |
| Revenue/Share | $0.23 | – |
| FCF/Share | $-0.39 | $-2.57 |
Profitability & Margins
| Metric | ABCL | DYN |
|---|---|---|
| ROE | -18.4% | -74.0% |
| ROA | -12.6% | -52.2% |
| ROIC | -17.9% | -58.6% |
| Operating Margin | -319.8% | – |
| Net Margin | -233.9% | – |
| EBT Margin | -279.5% | – |
| Tax Rate | 16.3% | – |
Financial Health
| Metric | ABCL | DYN |
|---|---|---|
| Current Ratio | 12.77x | 12.02x |
| Quick Ratio | 12.63x | – |
| D/E Ratio | 0.46x | 0.42x |
| Financial Leverage | 1.46x | 1.42x |
| Interest Coverage | – | -23.2x |
| Working Capital | $626M | $860M |
Cash Flow
| Metric | ABCL | DYN |
|---|---|---|
| Operating Cash Flow | -$95M | -$478M |
| Free Cash Flow | -$120M | -$480M |
| Capital Spending | -$25M | -$3M |
| FCF/Sales | -170.0% | – |
| CapEx/Sales | 35.1% | – |
Operational Efficiency
| Metric | ABCL | DYN |
|---|---|---|
| Asset Turnover | 0.05x | – |
| Receivables Turnover | 1.8x | – |
| Days Sales Outstanding | 199 days | – |
Income Statement
| Metric | ABCL | DYN |
|---|---|---|
| Total Revenue | $70M | – |
| Operating Income | -$225M | -$537M |
| Net Income | -$165M | -$519M |
| R&D Expense | $198M | $446M |
| SG&A Expense | $173M | – |
Dividend & Shareholder Information
| Metric | ABCL | DYN |
|---|---|---|
| Shares Outstanding | 307M | 187M |
ABCL vs DYN: stock comparison and AI forecast
Which is bigger, ABCL or DYN?
ABCL and DYN have similar market capitalizations ($3.41B and $3.23B).
Which stock performed better over the last six months, ABCL or DYN?
Over the last six months ABCL returned +142.3% and DYN -2.3%.
Which one does Intratio's AI model rank higher, ABCL or DYN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.